Inicio | Investigación e innovación | Programas Científicos | Programa de Investigación Clínica | Unidad de Investigación Clínica de Oncohematología Pediátrica IdiPAZ-CNIO

Antonio Pérez
Antonio Pérez Jefe de Unidad de Investigación Clínica
T +34 (+34) 917 328 000 (Ext )

Investigador Clínico I

  • Carmen Mestre

Becarios Post-doctorales

  • Cristina Aguirre
  • Halin Bareke
  • Adriana Mañas
  • Jordi Minguillón
  • Andrés París
  • Odelaisy León Triana

Becarios Pre-Doctorales

  • Karima Al Akioui
  • Laura Clares
  • Alfonso Navarro
  • Patricia Rodríguez
  • Beatriz Ruz

Técnicos de Laboratorio

  • Lidia Pertiñez
  • Natalia Riestra

The Pediatric Oncohematology Unit, led by Dr. Antonio Pérez Martínez, is a multidisciplinary team of physicians, geneticists, biologists, biochemists, and bioinformaticians, which for the last decade has enabled the development of projects ranging from knowledge generation to direct clinical application through the development of Clinical Trials. Our research focuses on the development of advanced therapies applied to pediatric oncology, infectious diseases, and pediatric transplantation. Briefly, our research interests include: 1) the use of hematopoietic stem cell transplantation as a platform for cell therapy, 2) the improvement of human stem cell progenitors transplantation in children, 3) cell therapy with memory T lymphocytes as adoptive immunotherapy, and 4) the use of both activated and memory like NK Cells and CART-T cells in pediatric oncology. Together with this, we led several projects aimed to study the efficacy and feasibility of cell therapy against infectious diseases. Finally, we are also working in the Induction of immunological tolerance in solid organ transplantation through the induction of mixed hematopoietic chimera through cell therapy.

We  maintain a strong commitment to the patients and the improvement of their quality of life, having a direct impact on the well-being of society. In this direction, we have several active academic clinical trials and collaborations with the industry with the objective of developing new and more effective therapies with fewer side effect.


    SELECT dxsjj_posts.* FROM dxsjj_posts LEFT JOIN dxsjj_postmeta ON ( dxsjj_posts.ID = dxsjj_postmeta.post_id ) LEFT JOIN dxsjj_postmeta AS mt1 ON ( dxsjj_posts.ID = mt1.post_id AND mt1.meta_key = 'factor_impacto' ) LEFT JOIN dxsjj_postmeta AS mt2 ON ( dxsjj_posts.ID = mt2.post_id ) LEFT JOIN dxsjj_postmeta AS mt3 ON ( dxsjj_posts.ID = mt3.post_id ) LEFT JOIN dxsjj_postmeta AS mt4 ON ( dxsjj_posts.ID = mt4.post_id ) WHERE 1=1 AND ( ( dxsjj_postmeta.meta_key = 'factor_impacto' OR mt1.post_id IS NULL ) AND mt2.meta_key = 'autores' AND ( mt3.meta_key = 'id_grupos' AND mt3.meta_value LIKE '{1563321efa027ccad0f07b704eda9175ee87e8fe46d4aa96c0084b8a7a90ea5b}50012146{1563321efa027ccad0f07b704eda9175ee87e8fe46d4aa96c0084b8a7a90ea5b}' ) AND ( mt4.meta_key = 'anyo' AND CAST(mt4.meta_value AS SIGNED) >= '2018' ) ) AND dxsjj_posts.post_type = 'cnio_publication' AND ((dxsjj_posts.post_status = 'publish')) GROUP BY dxsjj_posts.ID ORDER BY CAST(mt4.meta_value AS SIGNED) DESC, CAST(dxsjj_postmeta.meta_value AS SIGNED) DESC, CAST(mt2.meta_value AS CHAR) ASC